ATG7 regulates energy metabolism, differentiation and survival of Philadelphia chromosome-positive cells

Maria Karvela , Pablo Baquero , Elodie M. Kuntz , Arunima Mukhopadhyay, Rebecca Mitchell, Elaine K. Allan, Edmond Chan, Kamil R. Kranc, Bruno Calabretta , Paolo Salomoni , Eyal Gottlieb, Tessa L. Holyoake , G. Vignir Helgason

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

A major drawback of tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) is that primitive CML cells are able to survive TKI-mediated BCR-ABL inhibition, leading to disease persistence in patients. Investigation of strategies aiming to inhibit alternative survival pathways in CML is therefore critical. We have previously shown that a nonspecific pharmacological inhibition of autophagy potentiates TKI-induced death in Philadelphia chromosome-positive cells. Here we provide further understanding of how specific and pharmacological autophagy inhibition affects nonmitochondrial and mitochondrial energy metabolism and reactive oxygen species (ROS)-mediated differentiation of CML cells and highlight ATG7 (a critical component of the LC3 conjugation system) as a potential specific therapeutic target. By combining extra- and intracellular steady state metabolite measurements by liquid chromatography-mass spectrometry with metabolic flux assays using labeled glucose and functional assays, we demonstrate that knockdown of ATG7 results in decreased glycolysis and increased flux of labeled carbons through the mitochondrial tricarboxylic acid cycle. This leads to increased oxidative phosphorylation and mitochondrial ROS accumulation. Furthermore, following ROS accumulation, CML cells, including primary CML CD34+ progenitor cells, differentiate towards the erythroid lineage. Finally, ATG7 knockdown sensitizes CML progenitor cells to TKI-induced death, without affecting survival of normal cells, suggesting that specific inhibitors of ATG7 in combination with TKI would provide a novel therapeutic approach for CML patients exhibiting persistent disease.
LanguageEnglish
JournalAutophagy
Early online date11 May 2016
DOIs
Publication statusE-pub ahead of print - 11 May 2016

Fingerprint

Philadelphia Chromosome
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Energy Metabolism
Protein-Tyrosine Kinases
Myeloid Cells
Reactive Oxygen Species
Autophagy
Pharmacology
Myeloid Progenitor Cells
Carbon Cycle
Citric Acid Cycle
Oxidative Phosphorylation
Glycolysis
Liquid Chromatography
Mass Spectrometry
Cell Survival
Stem Cells
Therapeutics
Glucose
Survival

Keywords

  • tyrosine kinase inhibitor
  • chronic myeloid leukemia
  • ATG7

Cite this

Karvela , M., Baquero , P., Kuntz , E. M., Mukhopadhyay, A., Mitchell, R., Allan, E. K., ... Vignir Helgason, G. (2016). ATG7 regulates energy metabolism, differentiation and survival of Philadelphia chromosome-positive cells. Autophagy. https://doi.org/10.1080/15548627.2016.1162359
Karvela , Maria ; Baquero , Pablo ; Kuntz , Elodie M. ; Mukhopadhyay, Arunima ; Mitchell, Rebecca ; Allan, Elaine K. ; Chan, Edmond ; Kranc, Kamil R. ; Calabretta , Bruno ; Salomoni , Paolo ; Gottlieb, Eyal ; Holyoake , Tessa L. ; Vignir Helgason, G. / ATG7 regulates energy metabolism, differentiation and survival of Philadelphia chromosome-positive cells. In: Autophagy. 2016.
@article{2e584063fea34a7fba12f49670973505,
title = "ATG7 regulates energy metabolism, differentiation and survival of Philadelphia chromosome-positive cells",
abstract = "A major drawback of tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) is that primitive CML cells are able to survive TKI-mediated BCR-ABL inhibition, leading to disease persistence in patients. Investigation of strategies aiming to inhibit alternative survival pathways in CML is therefore critical. We have previously shown that a nonspecific pharmacological inhibition of autophagy potentiates TKI-induced death in Philadelphia chromosome-positive cells. Here we provide further understanding of how specific and pharmacological autophagy inhibition affects nonmitochondrial and mitochondrial energy metabolism and reactive oxygen species (ROS)-mediated differentiation of CML cells and highlight ATG7 (a critical component of the LC3 conjugation system) as a potential specific therapeutic target. By combining extra- and intracellular steady state metabolite measurements by liquid chromatography-mass spectrometry with metabolic flux assays using labeled glucose and functional assays, we demonstrate that knockdown of ATG7 results in decreased glycolysis and increased flux of labeled carbons through the mitochondrial tricarboxylic acid cycle. This leads to increased oxidative phosphorylation and mitochondrial ROS accumulation. Furthermore, following ROS accumulation, CML cells, including primary CML CD34+ progenitor cells, differentiate towards the erythroid lineage. Finally, ATG7 knockdown sensitizes CML progenitor cells to TKI-induced death, without affecting survival of normal cells, suggesting that specific inhibitors of ATG7 in combination with TKI would provide a novel therapeutic approach for CML patients exhibiting persistent disease.",
keywords = "tyrosine kinase inhibitor, chronic myeloid leukemia, ATG7",
author = "Maria Karvela and Pablo Baquero and Kuntz, {Elodie M.} and Arunima Mukhopadhyay and Rebecca Mitchell and Allan, {Elaine K.} and Edmond Chan and Kranc, {Kamil R.} and Bruno Calabretta and Paolo Salomoni and Eyal Gottlieb and Holyoake, {Tessa L.} and {Vignir Helgason}, G.",
year = "2016",
month = "5",
day = "11",
doi = "10.1080/15548627.2016.1162359",
language = "English",
journal = "Autophagy",
issn = "1554-8627",

}

Karvela , M, Baquero , P, Kuntz , EM, Mukhopadhyay, A, Mitchell, R, Allan, EK, Chan, E, Kranc, KR, Calabretta , B, Salomoni , P, Gottlieb, E, Holyoake , TL & Vignir Helgason, G 2016, 'ATG7 regulates energy metabolism, differentiation and survival of Philadelphia chromosome-positive cells' Autophagy. https://doi.org/10.1080/15548627.2016.1162359

ATG7 regulates energy metabolism, differentiation and survival of Philadelphia chromosome-positive cells. / Karvela , Maria; Baquero , Pablo; Kuntz , Elodie M.; Mukhopadhyay, Arunima; Mitchell, Rebecca; Allan, Elaine K.; Chan, Edmond; Kranc, Kamil R.; Calabretta , Bruno; Salomoni , Paolo; Gottlieb, Eyal; Holyoake , Tessa L.; Vignir Helgason, G.

In: Autophagy, 11.05.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - ATG7 regulates energy metabolism, differentiation and survival of Philadelphia chromosome-positive cells

AU - Karvela , Maria

AU - Baquero , Pablo

AU - Kuntz , Elodie M.

AU - Mukhopadhyay, Arunima

AU - Mitchell, Rebecca

AU - Allan, Elaine K.

AU - Chan, Edmond

AU - Kranc, Kamil R.

AU - Calabretta , Bruno

AU - Salomoni , Paolo

AU - Gottlieb, Eyal

AU - Holyoake , Tessa L.

AU - Vignir Helgason, G.

PY - 2016/5/11

Y1 - 2016/5/11

N2 - A major drawback of tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) is that primitive CML cells are able to survive TKI-mediated BCR-ABL inhibition, leading to disease persistence in patients. Investigation of strategies aiming to inhibit alternative survival pathways in CML is therefore critical. We have previously shown that a nonspecific pharmacological inhibition of autophagy potentiates TKI-induced death in Philadelphia chromosome-positive cells. Here we provide further understanding of how specific and pharmacological autophagy inhibition affects nonmitochondrial and mitochondrial energy metabolism and reactive oxygen species (ROS)-mediated differentiation of CML cells and highlight ATG7 (a critical component of the LC3 conjugation system) as a potential specific therapeutic target. By combining extra- and intracellular steady state metabolite measurements by liquid chromatography-mass spectrometry with metabolic flux assays using labeled glucose and functional assays, we demonstrate that knockdown of ATG7 results in decreased glycolysis and increased flux of labeled carbons through the mitochondrial tricarboxylic acid cycle. This leads to increased oxidative phosphorylation and mitochondrial ROS accumulation. Furthermore, following ROS accumulation, CML cells, including primary CML CD34+ progenitor cells, differentiate towards the erythroid lineage. Finally, ATG7 knockdown sensitizes CML progenitor cells to TKI-induced death, without affecting survival of normal cells, suggesting that specific inhibitors of ATG7 in combination with TKI would provide a novel therapeutic approach for CML patients exhibiting persistent disease.

AB - A major drawback of tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) is that primitive CML cells are able to survive TKI-mediated BCR-ABL inhibition, leading to disease persistence in patients. Investigation of strategies aiming to inhibit alternative survival pathways in CML is therefore critical. We have previously shown that a nonspecific pharmacological inhibition of autophagy potentiates TKI-induced death in Philadelphia chromosome-positive cells. Here we provide further understanding of how specific and pharmacological autophagy inhibition affects nonmitochondrial and mitochondrial energy metabolism and reactive oxygen species (ROS)-mediated differentiation of CML cells and highlight ATG7 (a critical component of the LC3 conjugation system) as a potential specific therapeutic target. By combining extra- and intracellular steady state metabolite measurements by liquid chromatography-mass spectrometry with metabolic flux assays using labeled glucose and functional assays, we demonstrate that knockdown of ATG7 results in decreased glycolysis and increased flux of labeled carbons through the mitochondrial tricarboxylic acid cycle. This leads to increased oxidative phosphorylation and mitochondrial ROS accumulation. Furthermore, following ROS accumulation, CML cells, including primary CML CD34+ progenitor cells, differentiate towards the erythroid lineage. Finally, ATG7 knockdown sensitizes CML progenitor cells to TKI-induced death, without affecting survival of normal cells, suggesting that specific inhibitors of ATG7 in combination with TKI would provide a novel therapeutic approach for CML patients exhibiting persistent disease.

KW - tyrosine kinase inhibitor

KW - chronic myeloid leukemia

KW - ATG7

UR - http://www.tandfonline.com/doi/full/10.1080/15548627.2016.1162359

U2 - 10.1080/15548627.2016.1162359

DO - 10.1080/15548627.2016.1162359

M3 - Article

JO - Autophagy

T2 - Autophagy

JF - Autophagy

SN - 1554-8627

ER -